Tariq Shafi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tariq Shafi has a total of 526 co-authors. Here are the top co-authors by number of shared publications:
- Bernard G. Jaar
Johns Hopkins University School of Medicine
25 shared publications Josef Coresh
Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University School of Medicine, Baltimore, MD
20 shared publications- Stephen M. Sozio
Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
20 shared publications - Julia J. Scialla
Departments of Medicine and Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia
16 shared publications Neil R. Powe
Department of Medicine, Zuckerberg San Francisco General Hospital, San Francisco, California; and
14 shared publications- L. Ebony Boulware
Duke University School of Medicine, Durham, USA
11 shared publications
Latest Publications
- 8 May 2026
"Mechanisms, Magnitude, and Consequence of Acute Estimated Glomerular Filtration Rate Change with Guideline-Directed Medical Therapy Initiation in Heart Failure".
Estimated glomerular filtration rate (eGFR) is a key metric for assessing and monitoring kidney function. In heart failure (HF) management, guideline-directed medical therapy (GDMT) medications such as renin-angiotensin-aldosterone system inhibitors (RAASi), mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) can initially cause a transient decrease in eGFR due to hemodynamic changes, such as a reduction in systemic and glomerular hypertension, reversal of hyperfiltration, and vasodilation in the glomerular vasculature. Despite the initial drop, long-term use of GDMT slows eGFR decline and, in the long term, lowers the risk of developing chronic kidney disease (CKD). However, a significant decline in eGFR (≥20-30% reduction) may require closer monitoring and treatment adjustments. Additionally, the combined effect of these agents on eGFR, when administered concurrently or sequentially, is not clearly understood and should be carefully considered. In conclusion, this review highlights the need for a collaborative approach between nephrologists and cardiologists to closely monitor and manage eGFR changes following GDMT initiation. Prompt alerts to clinicians via the electronic health record, patient education, regular assessment, and clinical review for sustained reduction in eGFR are strategies to maximize the use and subsequent reno-protective effect of GDMT in HF.
- 8 May 2026
"Mechanisms, Magnitude, and Consequence of Acute Estimated Glomerular Filtration Rate Change with Guideline-Directed Medical Therapy Initiation in Heart Failure".
Estimated glomerular filtration rate (eGFR) is a key metric for assessing and monitoring kidney function. In heart failure (HF) management, guideline-directed medical therapy (GDMT) medications such as renin-angiotensin-aldosterone system inhibitors (RAASi), mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) can initially cause a transient decrease in eGFR due to hemodynamic changes, such as a reduction in systemic and glomerular hypertension, reversal of hyperfiltration, and vasodilation in the glomerular vasculature. Despite the initial drop, long-term use of GDMT slows eGFR decline and, in the long term, lowers the risk of developing chronic kidney disease (CKD). However, a significant decline in eGFR (≥20-30% reduction) may require closer monitoring and treatment adjustments. Additionally, the combined effect of these agents on eGFR, when administered concurrently or sequentially, is not clearly understood and should be carefully considered. In conclusion, this review highlights the need for a collaborative approach between nephrologists and cardiologists to closely monitor and manage eGFR changes following GDMT initiation. Prompt alerts to clinicians via the electronic health record, patient education, regular assessment, and clinical review for sustained reduction in eGFR are strategies to maximize the use and subsequent reno-protective effect of GDMT in HF.
- Open Access
- 13 February 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (7) , 1658-1661
CKD-Associated Pruritus
- 13 February 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (7) , 1658-1661
Open AccessCKD-Associated Pruritus
- 9 February 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (6) , 1335-1338
Steroidal versus Nonsteroidal Mineralocorticoid Receptor Antagonists in CKD
An abstract is unavailable. This article is available as a PDF only.
- 9 February 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (6) , 1335-1338
Steroidal versus Nonsteroidal Mineralocorticoid Receptor Antagonists in CKD
An abstract is unavailable. This article is available as a PDF only.
- 10 December 2025
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 32 (5) , 411-421
Adequacy Measurement for the 21st Century: Revisiting Kt/Vurea
- 10 December 2025
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 32 (5) , 411-421
Adequacy Measurement for the 21st Century: Revisiting Kt/Vurea
- Open Access
- 27 November 2025
- Published by Elsevier in Kidney Medicine
- Vol. 8 (1)
Operationalizing Home Blood Pressure Monitoring for Dialysis Patients: An Effectiveness-Implementation Hybrid Study
- 27 November 2025
- Published by Elsevier in Kidney Medicine
- Vol. 8 (1)
Open AccessOperationalizing Home Blood Pressure Monitoring for Dialysis Patients: An Effectiveness-Implementation Hybrid Study
- Open Access
- 23 September 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 353-361
A Metabolomics Approach To Identify Metabolites Associated with Uremic Symptoms in Patients Receiving Maintenance Hemodialysis
Key Points: Uremic symptoms are common in patients with kidney failure, but the chemicals causing them are unknown. We used state-of-the-art untargeted metabolomics and rigorous analyses to search for metabolites associated with uremic symptoms. We identified metabolite-symptom associations but could not replicate findings and offer recommendations for future research. Background: The specific toxins causing uremic symptoms (nausea, vomiting, pruritus, fatigue, difficulty concentrating, and pain) in kidney failure remain unknown. We used untargeted metabolomics to identify plasma metabolites associated with uremic symptoms in patients receiving hemodialysis. Methods: We measured metabolites in plasma samples from Longitudinal US/Canada Incident Dialysis study participants at baseline (discovery; n =636) and year 1 (internal validation; n =260) and from Frailty Assessment in Renal Disease study participants (external validation; n =355). We used metabolite-wise linear models with empirical Bayesian inference to evaluate the association between metabolites and uremic symptom severity, adjusting for key covariates. We accounted for multiple testing using a false discovery rate ( P values adjusted for false discovery rate [pFDR]) for linear models and used two machine learning models to evaluate the association consistency. We defined association as significant if pFDR < 0.1 and consistent if it had medium or high importance in both machine learning models. Results: Participants had a mean age of 63 years, with uremic symptom prevalence ranging from 44% to 83%. We identified 627 previously characterized (known) and 35,558 unknown metabolite peaks. No known metabolites were significantly and consistently associated with uremic symptom severity across all cohorts. Within cohorts, retinol was negatively associated with nausea/vomiting in Longitudinal US/Canada Incident Dialysis at year 1, and indole-3-propionic acid was negatively associated with anorexia in Frailty Assessment in Renal Disease. Several unknown metabolites were associated with symptoms (lowest pFDR, 0.0004), but none were consistent across cohorts. Conclusions: We identified metabolites associated with uremic symptom severity, although findings were inconsistent across cohorts. This study highlights the need for additional research on uremic toxins and clinical outcomes.
- 23 September 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 353-361
Open AccessA Metabolomics Approach To Identify Metabolites Associated with Uremic Symptoms in Patients Receiving Maintenance Hemodialysis
Key Points: Uremic symptoms are common in patients with kidney failure, but the chemicals causing them are unknown. We used state-of-the-art untargeted metabolomics and rigorous analyses to search for metabolites associated with uremic symptoms. We identified metabolite-symptom associations but could not replicate findings and offer recommendations for future research. Background: The specific toxins causing uremic symptoms (nausea, vomiting, pruritus, fatigue, difficulty concentrating, and pain) in kidney failure remain unknown. We used untargeted metabolomics to identify plasma metabolites associated with uremic symptoms in patients receiving hemodialysis. Methods: We measured metabolites in plasma samples from Longitudinal US/Canada Incident Dialysis study participants at baseline (discovery; n =636) and year 1 (internal validation; n =260) and from Frailty Assessment in Renal Disease study participants (external validation; n =355). We used metabolite-wise linear models with empirical Bayesian inference to evaluate the association between metabolites and uremic symptom severity, adjusting for key covariates. We accounted for multiple testing using a false discovery rate ( P values adjusted for false discovery rate [pFDR]) for linear models and used two machine learning models to evaluate the association consistency. We defined association as significant if pFDR < 0.1 and consistent if it had medium or high importance in both machine learning models. Results: Participants had a mean age of 63 years, with uremic symptom prevalence ranging from 44% to 83%. We identified 627 previously characterized (known) and 35,558 unknown metabolite peaks. No known metabolites were significantly and consistently associated with uremic symptom severity across all cohorts. Within cohorts, retinol was negatively associated with nausea/vomiting in Longitudinal US/Canada Incident Dialysis at year 1, and indole-3-propionic acid was negatively associated with anorexia in Frailty Assessment in Renal Disease. Several unknown metabolites were associated with symptoms (lowest pFDR, 0.0004), but none were consistent across cohorts. Conclusions: We identified metabolites associated with uremic symptom severity, although findings were inconsistent across cohorts. This study highlights the need for additional research on uremic toxins and clinical outcomes.
- Open Access
- 23 September 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 344-352
Residual Kidney Function and Response of Left Ventricular Mass to Intensive Hemodialysis
Key Points: Residual kidney function does not modify the response of left ventricular mass (LVM) to frequent hemodialysis in patients with ESKD. Both anuric and nonanuric patients showed similar improvements in LVM with intensive hemodialysis. Changes in residual kidney function were not associated with response of LVM to frequent hemodialysis. Background: Frequent (6 times/wk) hemodialysis has been shown to reduce left ventricular mass (LVM) more than conventional (3 times/wk) hemodialysis in patients with ESKD. Previous work suggested that the LVM benefits of frequent hemodialysis might be attenuated in the presence of residual kidney function (RKF). We hypothesized that patients without RKF would have greater LVM reduction with frequent hemodialysis compared with patients with RKF. Methods: We analyzed data from the Frequent Hemodialysis Network (FHN) Daily (in-center) and Nocturnal (home-based) trials, which randomized patients with ESKD to either frequent or conventional hemodialysis over 12 months. RKF was evaluated through timed 24-hour urine collections, with anuria defined as urine output P = 0.18). At 12 months, both anuric and nonanuric patients experienced similar LVM reductions with frequent hemodialysis (mean change in log LVM: −0.11±0.23 versus −0.08±0.23; P = 0.44). No association was found between baseline urine volume and LVM response (rho=−0.002, P = 0.98 for frequent; rho=0.003, P = 0.97 for conventional hemodialysis). Changes in urine volume over 12 months did not correlate with LVM changes. In an exploratory analysis, LVM reduction correlated with urine volume decline in men (rho=0.23; P < 0.01) but not in women (rho= −0.19; P = 0.10; P interaction = 0.003). Conclusions: Both anuric and nonanuric patients experienced similar LVM reductions with frequent hemodialysis, and no association between urine output and LVM response was observed in the FHN trials. These data suggest that the response of LVM to frequent hemodialysis is independent of baseline RKF.
- 23 September 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 344-352
Open AccessResidual Kidney Function and Response of Left Ventricular Mass to Intensive Hemodialysis
Key Points: Residual kidney function does not modify the response of left ventricular mass (LVM) to frequent hemodialysis in patients with ESKD. Both anuric and nonanuric patients showed similar improvements in LVM with intensive hemodialysis. Changes in residual kidney function were not associated with response of LVM to frequent hemodialysis. Background: Frequent (6 times/wk) hemodialysis has been shown to reduce left ventricular mass (LVM) more than conventional (3 times/wk) hemodialysis in patients with ESKD. Previous work suggested that the LVM benefits of frequent hemodialysis might be attenuated in the presence of residual kidney function (RKF). We hypothesized that patients without RKF would have greater LVM reduction with frequent hemodialysis compared with patients with RKF. Methods: We analyzed data from the Frequent Hemodialysis Network (FHN) Daily (in-center) and Nocturnal (home-based) trials, which randomized patients with ESKD to either frequent or conventional hemodialysis over 12 months. RKF was evaluated through timed 24-hour urine collections, with anuria defined as urine output P = 0.18). At 12 months, both anuric and nonanuric patients experienced similar LVM reductions with frequent hemodialysis (mean change in log LVM: −0.11±0.23 versus −0.08±0.23; P = 0.44). No association was found between baseline urine volume and LVM response (rho=−0.002, P = 0.98 for frequent; rho=0.003, P = 0.97 for conventional hemodialysis). Changes in urine volume over 12 months did not correlate with LVM changes. In an exploratory analysis, LVM reduction correlated with urine volume decline in men (rho=0.23; P < 0.01) but not in women (rho= −0.19; P = 0.10; P interaction = 0.003). Conclusions: Both anuric and nonanuric patients experienced similar LVM reductions with frequent hemodialysis, and no association between urine output and LVM response was observed in the FHN trials. These data suggest that the response of LVM to frequent hemodialysis is independent of baseline RKF.
- 6 May 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (10) , 2061-2076
Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes
The global incidence of CKD continues to rise, with type 2 diabetes as a major contributor. At any stage of CKD, patients with concurrent CKD and type 2 diabetes are at heightened cardiovascular risk and have a greater likelihood of dying from cardiovascular causes than progressing to kidney failure. Consequently, the use of “four pillars” of CKD therapy, including renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitor, nonsteroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists, has been advocated to reduce cardiovascular-kidney risk. Although these therapies can mitigate cardiovascular and kidney events when used individually, the residual risks of these events remain high across major clinical trials testing these therapies separately as well as in real-world clinical settings. This raises the question about when to optimally initiate these therapies, including strategies that start these agents in rapid sequence, or even simultaneously, to reduce long-term risk, thereby mirroring best practices with rapid titration schedules in patients with heart failure. However, initiating all four therapies simultaneously in the setting of CKD has not yet been tested due to lack of data on safety and tolerability in this high-risk population. Data regarding the safety profile of rapid sequence initiation remain limited. Therefore, our aim was to review the existing evidence on the safety profiles of guideline-recommended therapies and discuss the challenges associated with rapid sequence initiation of these treatments in patients with CKD.
- 6 May 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (10) , 2061-2076
Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes
The global incidence of CKD continues to rise, with type 2 diabetes as a major contributor. At any stage of CKD, patients with concurrent CKD and type 2 diabetes are at heightened cardiovascular risk and have a greater likelihood of dying from cardiovascular causes than progressing to kidney failure. Consequently, the use of “four pillars” of CKD therapy, including renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitor, nonsteroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists, has been advocated to reduce cardiovascular-kidney risk. Although these therapies can mitigate cardiovascular and kidney events when used individually, the residual risks of these events remain high across major clinical trials testing these therapies separately as well as in real-world clinical settings. This raises the question about when to optimally initiate these therapies, including strategies that start these agents in rapid sequence, or even simultaneously, to reduce long-term risk, thereby mirroring best practices with rapid titration schedules in patients with heart failure. However, initiating all four therapies simultaneously in the setting of CKD has not yet been tested due to lack of data on safety and tolerability in this high-risk population. Data regarding the safety profile of rapid sequence initiation remain limited. Therefore, our aim was to review the existing evidence on the safety profiles of guideline-recommended therapies and discuss the challenges associated with rapid sequence initiation of these treatments in patients with CKD.
- Open Access
- 7 April 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 153, 107911
System Interventions to Achieve Early and Equitable Kidney Transplants (STEPS): Protocol for STEPS, a randomized comparative effectiveness clinical trial
- 7 April 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 153, 107911
Open AccessSystem Interventions to Achieve Early and Equitable Kidney Transplants (STEPS): Protocol for STEPS, a randomized comparative effectiveness clinical trial